Steering to be used of VITROS SARS CoV2 Antigen CLIA based mostly Check from Ortho Medical
Diagnostics
1. The VITROS SARS CoV2 Antigen assay is a chemiluminescent immunoassay supposed for the qualitative
detection of SARS-CoV-2 nucleocapsid antigens in nasopharyngeal (NP) specimens from people who
are suspected of COVID-19 inside one to 5 days of the onset of signs, or mid-turbinate specimens
collected from asymptomatic people.
2. The assay ought to be carried out in VITROS 3600 Immunodiagnostics system or VITROS 5600 / VITROS XT 7600
Built-in system from Ortho.
SKU:G61RHA20
AVAILABILITY:In Inventory with The Lowest Value within the Market
SHIPMENT:Identical Day Cargo Orders Earlier than 14
H00SIZE:20 Exams/KitSPECIFICITY:98.90%
Sort
Immunochromatography speedy check
Description
Lateral circulation immunochromatographic assay that adopted twin shade system.
For the qualitative detection of SARS-CoV-2 antigen from nasopharyngeal swab specimen.
The check incorporates colloid gold conjugate pad and a membrane strip pre-coated with antibodies particular to SARS-CoV-2 antigen on the check strains (T).
A visual black band (antibody-antigen-antibody gold conjugate advanced) seems on the check strains (T) If SARS-CoV-2 antigen is current within the specimen.
The management line (C) exhibits that check is carried out accurately.
Evaluated with panel specimen (n = 75) by PCR
Sensitivity: 90,2 %
Specificity: 100 %
Functions
COVID-19, Nasopharyngeal swabs
Calibration Vary
Qualitative
VITROS SARS CoV2 antigen assay – Procedural Steps: –
Stage 1: Nasopharyngeal swab specimen assortment:
1. Gather a nasopharyngeal swab specimen by inserting the sterile swab into the nostril.
2. Push the sterile swab till resistance is met on the stage of the turbinate.
3. Rotate the sterile swab a number of instances in opposition to the nasopharyngeal wall & depart it in place for
10 seconds to saturate the swab tip.
4. Take away the swab from the nostril fastidiously.
5. Place the swab specimen into the viral transport medium buffer tube and shut the tube tightly.
6. Transport the swab pattern in VTM to the laboratory in a chilly chain.
7. The pattern will be saved at Room temperature (Under 30◦C) for as much as 24 hrs from the time of
pattern assortment or at 2 – 8◦C for as much as 48 hrs from the time of pattern assortment.
Stage 2: Pattern preparation for testing:
1. Pattern preparation must be carried out in BSL-2 stage cupboard within the Laboratory.
2. Combine the swab specimen in VTM tube effectively (vortex roughly 3-5 seconds).
3. Switch 100 μL VITROS SARS-CoV-2 Antigen Extraction Buffer right into a labelled new pattern tube.
4. Add 400 μL viral pattern to the above tube (to take care of 1:Four ratio of extraction buffer: pattern)
5. Combine effectively (Cap/Plug the pattern tube and vortex roughly 3-5 seconds).
COVID-19 Ag Rapid Test, Cs |
|||
| R0182C | CTK Biotech | 20 | EUR 1.25 |
COVID-19 Ag Self-Test. Cs |
|||
| R0182CST | CTK Biotech | 1,2,5 | EUR 1.65 |
COVID-19 Ag Rapid Test External Control Kit |
|||
| C0182 | CTK Biotech | each | EUR 520 |
Flu A & Flu B & Covid-19 Ag Rapid Test |
|||
| GF101A3 | Shenzhen Lvshiyuan Biotechnology | 25 Test/kit | Ask for price |
Panbio COVID-19 AG RAPID T Device 25T NP |
|||
| 41FK10 | Abbott | 25 Tests/Kit | EUR 220 |
Panbio COVID-19 AG RAPID T DEVICE 25T NS |
|||
| 41FK11 | Abbott | 25 Tests/Kit | EUR 123.75 |
|
Description: The Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 is a β -coronavirus, which is an enveloped non-segmented positive-sense RNA virus 2. It is spread by human-to-human transmission via droplets or direct contact, and infection has been estimated to have a mean incubation period of 6.4 days and a basic reproduction number of 2.24-3.58. Among patients with pneumonia caused by SARS-CoV-2, fever was the most common symptom, followed by cough3. The main IVD assays used for COVID-19 employ real-time reverse transcriptase-polymerase chain reaction (RT-PCR) that takes a few hours 4. The availability of a cost-effective, rapid point- of-care diagnostic test is critical to enable healthcare professionals to aid in the diagnosis of patients and prevent further spread of the virus5. Antigen tests will play a critical role in the fight against COVID-19 |
|||
COVID-19 + Influenza A. B Ag Rapid Test, Cs |
|||
| R0188C | CTK Biotech | 1fi | Ask for price |
COVID-19 Ag Detection Kit (Colloidal Gold Immunochromatography) |
|||
| MBS398097-20Tests | MyBiosource | 20Tests | EUR 325 |
Truenat™ COVID-19 |
|||
| 601430005 | Molbio Diagnostics Private Limited | 5T | EUR 60 |
Truenat™ COVID-19 |
|||
| 601430020 | Molbio Diagnostics Private Limited | 20T | EUR 240 |
Truenat™ COVID-19 |
|||
| 601430050 | Molbio Diagnostics Private Limited | 50T | EUR 600 |
COVID-19 variant pack |
|||
| SB072 | Smartox Biotechnology | 0.5 | EUR 2325.81 |
|
Description: SARS-CoV-2 Spike (S) glycoprotein:Spike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein in a class I fusion protein that allows the virus to enter host cells.Variants package available:Some proteins of Sars-CoV-2 are identified as leading targets for COVID-19 therapies. SB-PEPTIDE offers a special pack pre-made peptide libraries of Spike protein including peptides from COVID-19 variants: UK COVID-19 variant B.1.1.7, South Africa COVID-19 variant B.1.351, Brazil COVID-19 variant B.1.1.248. SB-PEPTIDE offers additional plate containing only peptides with Spike S protein mutation of COVID-19 B.1.1.7, B.1.3.5.1 and B.1.1.248 (cited below).Variants package and Spike (S) glycoprotein peptide library can be used for T-cell assays, immune monitoring, antigen specific T-cell stimulation, T-cell expansion and cellular immune response. |
|||
COVID-19 Spike Antigen |
|||
| 30-2018 | Fitzgerald | 1 mg | EUR 400 |
|
Description: COVID-19 Spike recombinant antigen |
|||
COVID-19 Spike Antigen |
|||
| 30-2019 | Fitzgerald | 1 mg | EUR 400 |
|
Description: COVID-19 Spike recombinant antigen |
|||
Moderna COVID-19 Vaccine |
|||
| H7N7-319 | Creative BioMart | 1 vial | EUR 798.4 |
|
Description: Protein |
|||
SARS & COVID-19 coronavirus |
|||
| 3862 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3863 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
SARS & COVID-19 coronavirus |
|||
| 3864 | Virostat | each | EUR 330 |
|
Description: nucleoprotein |
|||
COVID-19 Negative Control |
|||
| MBS412771-05mL | MyBiosource | 0.5mL | EUR 100 |
COVID-19 Negative Control |
|||
| MBS412771-5x05mL | MyBiosource | 5x0.5mL | EUR 305 |
COVID-19 Nucleocapsid protein |
|||
| 30-2005 | Fitzgerald | 1 mg | EUR 700 |
|
Description: COVID-19 Nucleocapsid protein recombinant antigen |
|||
COVID-19 Nucleocapsid protein |
|||
| 30-2006 | Fitzgerald | 1 mg | EUR 700 |
|
Description: COVID-19 Nucleocapsid protein recombinant Antigen |
|||